Dr. Kirk Campbell is  Professor of Medicine, Vice Chair of the Department of Medicine for Diversity and Inclusion and Director of the Nephrology Fellowship Program at the Icahn School of Medicine at Mount Sinai. In addition to treating patients with kidney disease, Dr. Campbell leads an NIH-funded research program focused on podocyte cell biology, experimental glomerular disease and clinical trials in the rare kidney disease space. The work centers on advancing the understanding of the underlying mechanisms involved in glomerular disease progression while identifying potential targets for therapeutic intervention. Key findings include the identification of dendrin and the Hippo pathways target Yes-associated protein (YAP) as regulators of podocyte survival and plasminogen as a targetable biomarker in glomerular disease. He has been a principal investigator for clinical trials testing the safety and efficacy of agents in development for focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy and lupus nephritis. He received his medical degree from the University of Connecticut and completed a residency in internal medicine at Yale-New Haven Hospital. He then completed a clinical and research fellowship in Nephrology at the Mount Sinai Medical Center in New York.